Such data are not surprising, since COVID-19 patients, as in other diseases, have a high risk of developing sarcopenia since they often present with hypoxemia, myalgia, elevated serum levels of creatine kinase and of pro-inflammatory cytokines (“cytokine storm”), including interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) which, similar to interferon, have been implicated in the pathogenesis of sarcopenia [10,11,12]. The gene discussed is IL6; the disease is COVID-19.